Dr. Saeidreza Harirforoosh
- Education:
- Tehran University of Medical Sciences, Doctor of Pharmacy
University of Alberta, Ph.D.
Biography
Dr. Saeidreza "Sam" Harirforoosh joined Chapman University School of Pharmacy (CUSP) as an instructional Professor of Biomedical Pharmaceutical Sciences in 2022. He received his PharmD from Tehran University of Medical Sciences in 1991, and his PhD in Pharmaceutical Sciences (Pharmacokinetics) from the University of Alberta in 2005. His dissertation focused on the area of pharmacokinetics and renal effects of nonsteroidal anti-inflammatory drugs. He also worked as a research assistant/post-doctoral fellow at the University of Alberta, Department of Medicine, from summer 2005 to spring 2006.
Prior to joining CUSP, he was a tenured professor in the Department of Pharmaceutical Sciences at East Tennessee State University, Gatton College of Pharmacy. He coordinated and taught courses in pharmacokinetics, pharmacogenomics, and drug metabolism. Dr. Harirforoosh is a registered pharmacist in the province of Alberta, Canada.
Over the last several years, he has authored/co-authored 44 peer-reviewed articles and 80 abstracts; served on the editorial boards of the journals of Clinical Pharmacokinetics and European Journal of Drug Metabolism and Pharmacokinetics; delivered several lectures at local, national and international conferences; received two research awards from the Gatton College of Pharmacy for his achievements in research and one Gatton College of Pharmacy outstanding teacher award (presented by the class of 2017); served as an abstract reviewer, a grant reviewer, and a peer reviewer for numerous scientific journals; and served as a research advisor for 40 PhD, PharmD, MPH, and undergraduate students.
Recent Creative, Scholarly Work and Publications
-
Fankhouser, R. W., Murrell, D. E., Anane, Y. Y., Hurley, D. L., Mamudu, H. M., & Harirforoosh, S. (2022). Type 2 diabetes: an exploratory genetic association analysis of selected metabolizing enzymes and transporters and effects on cardiovascular and renal biomarkers. Drug Metab Pers Ther, 37(4), 375-382.
-
Omoike, O. E., Paul, T. K., Ridner, S. L., Awasthi, M., Harirforoosh, S., & Mamudu, H. M. (2020). Association between smoking status and homocysteine levels and possible effect modification by cholesterol and oestradiol. Biomarkers, 25(2), 126-130.
-
Murrell, D. E., Cluck, D. B., Moorman, J. P., Brown, S. D., Wang, K. S., Duffourc, M. M., & Harirforoosh, S. (2019). HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study. Clin Drug Investig, 39(3), 285-299.
-
Thigpen, J. C., Odle, B. L., & Harirforoosh, S. (2019). Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children. Eur J Drug Metab Pharmacokinet, 44(5), 591-609.
-
Pond, B. B., Brown, S. D., Stewart, D. W., Roane, D. S., & Harirforoosh, S. (2019). Faculty Applicants' Attempt to Inflate CVs Using Predatory Journals. Am J Pharm Educ, 83(1), 7210.
-
Salwan, A. J., Hagemeier, N. E., & Harirforoosh, S. (2018). Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters? Clin Drug Investig, 38(7), 573-577.
-
Chen, Y., Xu, C., Harirforoosh, S., Luo, X., & Wang, K. S. (2018). Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol. J Psychiatr Res, 96, 65-72.
-
Mamudu, H. M., Subedi, P., Paul, T., Alamin, A. E., Alamian, A., Wang, L., Stewart, D., Jones, A., Harirforoosh, S., Blackwell, G., & Budoff, M. (2018). The associated risk factors for coronary artery calcium in asymptomatic individuals with and without diabetes in rural Central Appalachia. J Diabetes Complications, 32(10), 900-905.